Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: BLOOD AND TUMOR.
- Who it may be relevant to
- Registry conditions: Cancer of the Colon. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Our goal is to create novel CD47-SIRPα inhibitors using small molecules to reverse TAM-mediated immune suppression and restore anti-tumor immunity in CRCs. Our program uses structure-based drug design to create selective and potent small molecule inhibitors of SIRPα-CD47 to target the tumor microenvironment with greater efficacy and lower toxicity than CD47-targeting antibodies. . In order to study the activity of CD47-SIRPα inhibitors on the immune microenvironment of tumors, we propose to use organoids derived from biopsies of patients with colon cancer. Tumoroids preserve the patient's tumor stroma (including myeloid cells) and provide an accurate in vitro model of complex tumor immune interaction for the evaluation of immunotherapies.
Interventions
- Procedure BLOOD AND TUMOR
sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece
Primary outcome measures
- Establishment of patient derived organoids (minimum n=30) resembling the primary tissue sample [Time frame: 18 months from study launch]
Secondary outcome measures (3)
- Establishment of a validated cryobank of patient derived organoids (minimum n=30) [Time frame: 18 months from study launch]
- Generate a T cell biobank by FACS isolating T cells using the CD3 surface marker directed against the human form [Time frame: 48 month]
- To assess the effect of immunotherapy on the antitumor activity of autologous T cells from peripheral blood samples using tumor viability measurements (cell titer glo, FACS) [Time frame: 48 month]
Eligibility criteria
Inclusion criteria
- Patient over 18 years old
- Patient who has signed a consent to participate;
- Patient with metastatic or non-metastatic colon cancer, or recurrence of colon cancer for whom excision surgery has been proposed;
- Patient affiliated to a social security scheme, or beneficiary of such a scheme
Exclusion criteria
- Patient who had emergency colon cancer surgery
- Person in an emergency situation or unable to express their consent.
- Adult subject to a legal protection measure (adult under guardianship, curatorship or safeguard of justice),
- Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
France · 1 center
- Institut Paoli Calmettes — Marseille
Identifiers
NCT: NCT05955196 · MACROSWITCH-IPC 2021-083